PFG Advisors’s VanEck Biotech ETF BBH Stock Holding History

PFG Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,112	Closed	-$260K	–	311
2019 Q1	$260K	Sell	2,112 -184	-8%	-$23.2K	0.08%	237
2018 Q4	$290K	Buy	2,296 +39	+2%	+$4.71K	0.09%	227
2018 Q3	$279K	Buy	2,257 +10	+0.4%	+$1.3K	0.22%	119
2018 Q2	$270K	Buy	+2,247	New	+$265K	0.24%	109

Other funds holding BBH

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

BRM

Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return

PFG Advisors's BBH Position: Q2 2019 in Review

PFG Advisors sold out of VanEck Biotech ETF (BBH) in Q2 2019, closing a stake of 2,112 shares — an estimated $260K sold.

PFG Advisors first reported a position in BBH in Q2 2018 and held it in 4 quarters. The position peaked at $290K in Q4 2018. 84 funds tracked by Wall St. Rank hold BBH as of Q2 2019.

PFG Advisors reported no remaining VanEck Biotech ETF position as of Q2 2019 after selling out during the quarter.
PFG Advisors sold 2,112 VanEck Biotech ETF shares in Q2 2019, an estimated $260K.
PFG Advisors first reported a position in VanEck Biotech ETF in Q2 2018 and held it in 4 quarters.
PFG Advisors's VanEck Biotech ETF position peaked at $290K in Q4 2018.
84 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2019.

Based on PFG Advisors's 13F filing for Q2 2019, filed 5 Aug 2019.